PARP1 and cancer: Here, we discover and characterize an allosteric Polθ-pol inhibitor class (RTx-161/RTx-152) that exhibits 4–6 nM IC50, selectively kills HR-deficient cancer cells, and suppresses PARP inhibitor (PARPi) resistance in multiple genetic backgrounds, including HR-proficient cells.